MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
1.010
+0.029
+2.94%
After Hours: 0.9800 -0.03 -2.97% 19:59 03/17 EDT
OPEN
1.000
PREV CLOSE
0.9812
HIGH
1.040
LOW
0.9715
VOLUME
6.77M
TURNOVER
--
52 WEEK HIGH
3.179
52 WEEK LOW
0.3040
MARKET CAP
210.73M
P/E (TTM)
-1.3559
1D
5D
1M
3M
1Y
5Y
1D
SANGAMO THERAPEUTICS, INC. (Form 10-K)
Press release · 5h ago
Sangamo Therapeutics Inc. Q4 Loss Drops
NASDAQ · 5h ago
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 6h ago
Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 6h ago
Sangamo Therapeutics GAAP EPS of -$0.11 misses by $0.02, revenue of $7.55M misses by $4.15M
Seeking Alpha · 7h ago
Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate
Benzinga · 7h ago
BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11 Vs. IBES Estimate USD -0.09
Reuters · 7h ago
SANGAMO THERAPEUTICS Q4 OPERATING EXPENSES USD 33.5 MILLION
Reuters · 7h ago
More
About SGMO
More
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Recently
Symbol
Price
%Change

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.